Dren Bio raises $350M oversubscribed round to advance CD94 antibody toward registration
- Dren Bio closed an oversubscribed $350M round co-led by Juvia Group and Lightspeed Venture Partners.
- Proceeds will support late-stage development and regulatory and commercial preparation for dibotatug, a CD94-targeting antibody in Phase 1/2 for cytotoxic T cell lymphoma and large granular lymphocytic leukemia.
- Sanofi paid $600M upfront in 2025 for the company's bispecific myeloid cell engager.
💡 Points Based on public reports
A $350M private round for a Phase 1/2 asset signals Dren wants to take dibotatug toward registration itself rather than license it early. Ultra-rare indications like LGL leukemia make a lean, self-run launch plausible. With Sanofi's $600M upfront already validating the myeloid engager, Dren looks set to keep the economics of its CD94 asset.
Dren Bio lands $350M to push rare blood cancer therapy toward market ↗